Shopping Cart

Remove All
Your shopping cart is currently empty

Proceed to checkout Continue shopping

Immunology/Inflammation

Aryl Hydrocarbon Receptor

Immunology/Inflammation related

NOD-like Receptor (NLR)

Prostaglandin Receptor

Reactive Oxygen Species

Thrombopoietin Receptor

BCL6

BCL6 (B-cell lymphoma 6) is a zinc finger transcription factor that acts as a key regulator of B cell development and immune responses. It functions primarily as a transcriptional repressor, controlling genes involved in cell proliferation, apoptosis, and differentiation. BCL6 is essential for the formation of germinal centers during humoral immunity, where it regulates B cell maturation and antibody production. Dysregulation of BCL6 is associated with lymphomas, particularly diffuse large B-cell lymphoma (DLBCL), where it promotes cell survival and proliferation. Due to its critical role in immunity and cancer, BCL6 is a potential therapeutic target in hematological malignancies.

Filter HomeSignaling PathwaysImmunology/InflammationBCL6

ARV-393

T843162851885-95-3

ARV-393 is a PROTAC degrader targeting BCL6 with the advantage of being highly potent and orally available.ARV-393 recruits BCL6 and E3 ligase cerebellum to rapidly degrade BCL6 through the cell's natural ubiquitin proteasome system for the treatment of diffuse large b-cell lymphoma (DLBCL) and non-Hodgkin's lymphoma (NHL).

$223

In Stock

Size

QTY

BI-3802

T54082166387-65-9

BI-3802, a highly potent BCL6 degrader, targets and inhibits the Bric-à-brac (BTB) domain of BCL6, exhibiting an IC50 value of ≤3 nM. It induces polymerization of BCL6 and facilitates its degradation in a manner dependent on the E3 ligase SIAH1, demonstrating notable antitumor activity[1][2].

$127

In Stock

Size

QTY

ARV-393 HCl

T84316L In house

ARV-393 HCl is an orally active and potent PROTAC targeting BCL6 with antitumor activity for the study of non-Hodgkin's lymphoma.

$226

In Stock

Size

QTY

BCL6-IN-3

T104872253878-44-1

BCL6-IN-3 is a potent BCL6 inhibitor with GI50 of 70 nM in SU-DHL4 cells. BCL6-in-3 regulates cell activation, differentiation, DNA damage and apoptosis, and has antitumor activity.

$117

In Stock

Size

QTY

FX1

T40891426138-42-2

FX1 is an effective and selective BCL6 inhibitor (IC50: 35 μM).

In Stock

Size

QTY

BCL6-IN-6

T600082408882-54-0

BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.

In Stock

Size

QTY

CID5721353

T3940301356-95-6

CID5721353 (BCL6 inhibitor) is a B-Cell Lymphoma 6 Inhibitor (BCL6 inhibitor) that disrupts BCL6/corepressor complexes in vitro and in vivo, and was shown to bind the critical site within the BTB groove.

In Stock

Size

QTY

TL4-12

T262801620820-12-3

TL4-12 is a specific MAP4K2/GCK inhibitor that inhibits IKZF1 and BCL-6.TL4-12 inhibits MM cell proliferation and induces apoptosis, and can be used in the study of multiple myeloma (MM).

In Stock

Size

QTY

BCL6-IN-7

T87312097518-46-0

BCL6-IN-7 (BCL6 inhibitor-7) is a BCL6 co-repressor interaction inhibitor with potential anticancer activity. It can be used for studying lymphomas.

In Stock

Size

QTY

BI-3812

T145612166387-64-8

BI-3812 is an inhibitor of BCL6. Which inhibiting the BTB domain of BCL6 (IC50: 3 nM). BI-3812 also has antitumor activity.

$112

In Stock

Size

QTY

OICR11029

T2050402374711-65-4

OICR11029 is a potent probe for Bcl-6.

Inquiry Price

Size

QTY

EB-TCIP

T206944

EB-TCIP (BAK-04-212) is a bivalent molecule composed of AP1867 and BI-3812. It facilitates the reversible formation of a ternary complex between FKBPF36V and BCL6BTB, thereby recruiting FKBP12F36V-tagged EWS/FLI1 to DNA sites bound by the transcriptional regulator BCL6, rapidly inducing expression of BCL6 target genes such as SOCS2 and CXCL11. EWS/FLI1 is a fusion transcription factor found in Ewing sarcoma. EB-TCIP is applicable for studying transcriptional dysregulation in cancer.

Inquiry Price

Size

QTY

CDK-TCIP2

T201211

DK-TCIP2 is an anticancer agent formed by linking the CDK9 inhibitor SNS-032 and the BCL6 inhibitor BI-3812. This compound exhibits anticancer activity both in vivo and in vitro, making it suitable for research in lymphoma.

Inquiry Price

Size

QTY

Go to page 1

Page of 1